Q4 2025 Earnings Call March 12, 2026 4:30 PM EDTCompany ParticipantsJennie WillsonJacqueline Shea - CEO, President ...

Boron agents termed GluBs, developed by Science Tokyo researchers, have overcome a key limitation in cancer therapy by entering tumor cells through a pathway that standard drugs cannot use. The GluBs ...

FibroBiologics, Inc. (Nasdaq: FBLG) ('FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures ...

A new preclinical study in mice shows that precancerous cells in the pancreas can be eliminated before they have the chance to become tumors.

Application supported by Phase 3 data reinforcing teclistamab regimens as a potential standard of care after at least one prior therapy1 ...

Researchers from Australian National University and Longi used photoluminescence imaging to analyze dopant distributions in RCz-grown silicon wafers doped with antimony, phosphorus, and gallium, ...

FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development ...

CIA Season 1 Episode 3 episode opens with Nikki volunteering to travel to Beijing, where the situation escalates rapidly. The Fusion Cell coordinates efforts to ensure her safe return.

Enrollment continues to progress in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis Phase 2 TRITON trial of Descartes-08 in dermatomyositis and antisynthetase syndrome, expected to initiate ...

Approval based on unprecedented Phase 3 data demonstrating statistically significant improvements in progression-free survival and overall survival versus standard of care regimens83.3% of ...

Investigators are exploring whether combinational therapies can improve survival for patients with renal cell carcinoma or muscle-invasive bladder cancer.